






(2R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



I


AB We have developed an efficient and selective radioligand, the [<sup>35</sup>Si]-radiolabeled dihydroquinoxaline derivative, I, for an ex vivo receptor occupancy assay in transgenic rats over-expressing the human bradykinin B<sub>1</sub> receptor.

IT 714564-55-3P 714564-94-0P 714565-08-9P  
714555-23-8P 714555-27-2P 714555-60-3P

RU: BUU (Biological study, unclassified); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PRPP (Preparation) (efficient and selective radioligand for bradykinin B<sub>1</sub> receptor occupancy studies)

RN 714564-55-3 CAPLUS  
CN 2-Quinoxalineacetamide, 1-[3,4-dichlorophenyl]phenyl-1,2,3,4-tetrahydro-3-oxo-, (2R)- dihydro-1H-imidazol-2-yl)phenyl-1,2,3,4-tetrahydro-3-oxo-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 714565-08-9 CAPLUS  
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]ethyl]-3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 714565-23-8 CAPLUS  
CN 2-Quinoxalineacetamide, 1,2,3,4-tetrahydro-1-(4-(1H-imidazol-2-yl)phenyl)ethyl)-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)



RN 714564-94-0 CAPLUS  
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 714564-94-0 CAPLUS  
CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-,




RN 714565-27-2 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-60-3 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-98-7 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-N-[2-[4-(1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 808770-57-2 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED  
 INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

ACCESSION NUMBER: 2004-750984 CAPLUS  
DOCUMENT NUMBER: 141-34321  
TITLE: Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist

AUTHOR(S): Ranson, Richard W.; Harrell, Charles M.; Reiss, Duane R.; Murphy, Kathryn L.; Chang, Raymond S. L.; Hess, J. Fred; Miller, Patricia J.; O'Malley, Stacey S.; Rey, Pat J.; Kunapuli, Priya; Su, Dai-Shi; Markowitz, M. Kristine; Wallace, Michael A.; Raab, Conrid B.; Jones, Allen N.; Dean, Dennis C.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.



CORPORATE SOURCE: Department of Molecular Neurology, WP46-300, Merck Research Laboratories, West Point, PA, 19486, USA  
European Journal of Pharmacology (2004), 499(1-2), 77-84

SOURCE: CODEN: EUPHAZ; ISSN: 0014-2999  
Elsevier B.V.

PUBLISHER: Journal

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Compound A (N-[2-[(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-2-[2R]-1-(2-naphthylsulfonyl)-3-oxo-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


PAGE 2-A

● HCl

IT 808770-58-3P  
RU: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
BR: (Efficient and Selective radioligand for bradykinin B1 receptor occupancy studies)

RN 808770-58-3 CAPLUS  
CN 2-Quinoxalineacetamide, N-[2-[(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT  
RU: (Biological study)  
(Pharmacol. characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist)

RN 714554-55-3 CAPLUS  
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:




RN 71455-13-6 CAPLUS  
CN 2-Quinoxalineacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-3,4-tetrahydro-1-(2-naphthalenylsulfonyl)]-3-oxo-,  
(2R)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004-531163 CAPLUS  
DOCUMENT NUMBER: 41-89112  
TITLE: Preparation of quinoxalines as bradykinin B1 antagonists for the treatment of pain and inflammation.  
INVENTOR(S): Su, Dai -shi; Bock, Mark G. ✓  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 51 pp.  
PATENT: P1XXD2  
DOCUMENT TYPE:




AB Title compds. I [X = (CH<sub>2</sub>)<sub>m</sub>CONR<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>PO<sub>2</sub>, etc.; m = 0-2; R<sub>2</sub> = H, alkyl; Y = CO, CO<sub>2</sub>, SO<sub>2</sub>, etc.; R<sub>1</sub> = (un)substituted (CH<sub>2</sub>)<sub>n</sub>-phenyl; n = 0-10; R<sub>2</sub> = (un)substituted alkyl, cycloalkyl, aryl, etc.; R<sub>3a</sub>, R<sub>3b</sub> = H, halo, alkyl, etc.; R<sub>4</sub> = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, condensation of ethylene diamine and cyanophenyl II (R = CN), e.g., prepared from di-methoxy D-aspartate in 5-steps, afforded dihydro-1H-imidazol II (R = C≡NCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) in 55% yield. In human bradykinin B1-B2 receptor binding assays, compds. I exhibited affinity for the B<sub>1</sub> receptor at least 10-fold, and preferably over 100-fold, over that for the B<sub>2</sub> receptor (sic). Compds. I are claimed useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

IT 71454-5-3P 71456-60-0P 71456-63-5P  
71454-68-9P 71456-79-1P 71456-84-8P  
71456-83-3P 71456-99-0P 714564-99-5P  
71455-04-5P 714565-08-9P 714565-13-6P  
71455-18-1P 714565-23-8P 714565-27-2P


APPLICANTS






RN 714564-84-8 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-difluorobenzoyl)-N-[2-[(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714564-94-0 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714564-99-5 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714564-99-5 CAPLUS  
 CN 2-Quinoxalineacetamide, N-[2-[(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethyl]-1,2,3,4-tetrahydro-3-oxo-1-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-04-5 CAPLUS  
 CN 2-Quinoloneacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-13-6 CAPLUS  
 CN 2-Quinoloneacetamide, N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-08-9 CAPLUS  
 CN 2-Quinoloneacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714565-18-1 CAPLUS  
 CN 2-Quinoloneacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-7-fluoro-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 714565-22-8 CAPLUS  
 CN 2-Quinoxalineacetamide, 1,2,3,4-tetrahydro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-32-9 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-1-(phenylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-38-5 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-(3,4-dichlorobenzoyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-27-2 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1-(2-naphthalenylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-51-2 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(4-chlorobenzoyl)-N-[2-[(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-64-7 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-N-[2-[(4-(1H-imidazol-1-yl)phenyl)ethyl]-1-(2-naphthalenylsulfonyl)]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714565-60-3 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[(4-(1H-imidazol-1-yl)phenyl)ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714565-78-3 CAPLUS  
 CN 2-Quinoxalineacetamide, N-[2-[(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(2-naphthalenylcarbonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714565-94-3 CAPLUS

CN 2-Quinoxalineacetamide, 7-chloro-1,2,3,4-tetrahydro-1-(2-naphthalenylsulfonyl)-3-oxo-N-[2-[4-(4H-1,2,4-triazol-4-yl)phenyl]ethyl]-, (2R)- (9CI) [CA INDEX NAME]


Absolute stereochemistry.



RN 714565-98-7 CAPLUS

CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) [CA INDEX NAME]


Absolute stereochemistry.



RN 714566-02-6 CAPLUS

CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) [CA INDEX NAME]


Absolute stereochemistry.



RN 714566-13-9 CAPLUS


CN 2-Quinoxalineacetamide, 1-[(5-chloro-2-thienyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) [CA INDEX NAME]

Absolute stereochemistry.




RN 714566-22-0 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[2-[4-(4-morpholinyl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714566-27-5 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[4-(4-morpholinyl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714566-43-5 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[4-(4-morpholinyl)phenyl]ethyl]-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714566-61-7 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3-chlorobenzoyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 71456-65-1 CAPLUS  
 CN 1-(2H-Quinoxalinecarboxylic acid, 2-[2-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]amino]-2-oxo-, (2R)- (9CI) (CA INDEX NAME)  
 (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 71456-44-9 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-1H-imidazol-2-ylphenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:



RN 714567-54-1 CAPLUS  
 CN 2-Quinoxalineacetamide, 1-(cyclohexylcarboxyyl)-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-, (2R)- (9CI) (CA INDEX NAME)  
 (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry:



RN 714567-65-4 CAPLUS  
 CN 2-Quinoxalineacetamide, 7-chloro-N-[2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-1-(methylsulfonyl)-3-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry:

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:




RN 714567-75-6 CAPLUS  
CN 1-(2H)-Quinoxalineacetic acid, 2-[2-[(2-[(4-5-dihydro-1H-imidazol-2-yl)phenyl]ethyl)amino]-2-oxo-]3,4-dihydro-3-oxo-, 1,1-dimethyl-ethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2  
THREE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200309345	A1	20031113	WO 2003-US13105	20030502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, ES, PT, GB, GI, GE, GH, GM, HR, HO, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UR, UG, US, UZ, VC, VN, YU, ZA, ZW,				
FW: GH, GM, KE, LS, MR, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, HU, IR, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GH, MR, NE, SN, TD, TG				
US 2004147519	A1	20040729	US 2003-429203	20030502
US 2004147520	A1	20040729	US 2003-429917	20030502
PRIORITY APPN. INFO.:				
OTHER SOURCE(S):				
GI				

AB Title compd. I (wherein n = 0-4; p = 0-1; q = 0-1; Y = O, S, OR8, NR8, or SR8; W = O, S, or N, when W = O or S, then q = 0, when W = N, then q = 1; R = (un)substituted (hetero)aryl or heterocyclyl; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkynyl, alkynyl, (hetero)aryl, or heterocyclyl; or NR1R2 = (un)substituted (hetero)aryl or heterocyclyl); R3 = independently (un)substituted (cyclo)alkyl, alkynyl, alkyne, amino, (hetero)alkyloxy, heterocyclyloxy, acyloxy, (cyclo)alkyl, alkenyl, (hetero)aryl, heterocyclyl, or acyl(oxyl); R8 = (un)substituted (cyclo)alkyl, (hetero)aryl, heterocyclyl, or acyl(oxyl); with provisos: and pharmaceutically acceptable salts thereof) were prepared as bradykinin antagonists. For example, condensation of 2-[(1-(4-chloro-2,5-dimethylbenzenesulfonyl)-3-oxo-1,2,3,4-tetrahydroquinolin-2-yl)acetic acid and 4-(2-(tert-butoxycarbonyl)amino)ethyl]piperidine in the presence of TEA and DPPA in DMF afforded II. Compsd. of the invention inhibited the bradykinin B1 receptor in IMR-90 human lung fibroblast cells with IC50 values of 0.1 nM to 10,000 nM. Thus, I are useful for relieving symptoms associated with

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 391 pp.  
CODEN: PIXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003-892158 CAPLUS  
DOCUMENT NUMBER: 139-35948  
TITLE: Preparation of butenylquinolone acetamide derivatives and related compounds as bradykinin antagonists  
INVENTOR(S): Grant, Francine; Bartulis, Sarah; Brogley, Louie; Dappan, Michael S.; Kadar, Ramesh; Khan, Amin; Neitzel, Marvin; Pleiss, Michael A.; Thorsett, Eugene D.; Tucker, John; Ye, Michael; Hawkinson, John  
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 391 pp.  
CODEN: PIXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English

bradykinin, including pain, inflammation, bronchoconstriction, cerebral edema etc (no data).

(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl]-1,2,3,4-tetrahydro-3-oxo-  
(9CI) (CA INDEX NAME)

KU: KTC (Kinaesthetic control); SYN (Synthetic preparation); INTR (Therapeutic use); BIOL (Biological study); PREP (Preparation); USESS

(USES) bradykinin B1 antagonist; preparation of (quinoxalinyl)acetamides and related compds. as bradykinin antagonists for treatment of pain, inflammation, and other disorders

RN 62543-79-1 CAPTIS  
 CN 2-Quinolinalacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-1-[(1R)-2-oxo-1-[(4-(2-pyrimidinyl)phenyl)methyl]-2-(1-pyridinyl)ethyl]-, (2R)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 625441-13-6 CAPIUS  
CN 2-Quinoxalineacetam.

1-[1-(4-(5-dimethyl-1H-imidazo-2-yl)phenyl)methyl]-2,2-dioxo-2-(1-pyridylmethyl)-1,2,3,4-tetrahydro-3-oxo-, trifluoroacetate (9CI) (CA INDEX NAME)

RN 625438-80-4 C1H13N2O4  
 CN CAPIUS  
 2-Quinolino[3,4-d]oxetan-1-yl-1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-oxo-1-[(1R)-2-oxo-1-[(4-(2-pyrimidinyl)phenyl)methyl]-2-(1-pyridinyl)ethyl]-, (2S)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




CM 2

RN 625440-78-0 CAPLUS  
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-[2-[(4-


RN 625441-15-8 CAPIUS  
2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-N-[(1R)-  
1-[(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)methyl]-2-oxo-2-(1-  
pyrrolidinyl)ethyl]-1,2,3,4-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625442-21-1 CAPIUS  
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-  
tetrahydro-N-[(1S)-1-[(4-(1H-imidazol-2-yl)phenyl)methyl]-2-oxo-2-(1-  
pyrrolidinyl)ethyl]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625442-21-1 CAPIUS  
CN 2-Quinoxalineacetamide, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-1,2,3,4-  
tetrahydro-N-[(1S)-1-[(4-(1H-imidazol-2-yl)phenyl)methyl]-2-oxo-2-(1-  
pyrrolidinyl)ethyl]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 7



THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RUE FORMAT



RN 565460-53-9 CAPIUS  
CN 2-Quinoxalineacetamide, 1-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-  
tetrahydro-N-[(2R)-1-[(4-(1H-imidazol-2-yl)phenyl)methyl]-2-oxo-2-(1-  
pyrrolidinyl)ethyl]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPIUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2003-418208 CAPIUS  
DOCUMENT NUMBER: 139-127923  
TITLE: Discovery of a Potent, Non-peptide Bradykinin B1  
Receptor Antagonist  
S. Di-Shi; Markowitz, M. Kristine; DiPardo, Robert  
M.; Murphy, Kathy L.; Harrell, C. Meacham; O'Malley,  
Stacy S.; Ransom, Richard W.; Chang, Raymond S. L.;  
Ha, Sookhee; Hess, Fred J.; Pettibone, Douglas J.;



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003-75620 CAPLUS  
DOCUMENT NUMBER: 138:13112

Tetrahydroquinolines acting as bradykinin antagonists, their preparation, and their therapeutic use

Byreuther, Bettina; Hahn, Michael; Kallus, Christopher; Kruger, Joachim; Meier, Heinrich; Reissmuller, Elke; Telian, Leila; Wittka-Nopper,

Reilinde; Kroll, Matthias; Beyer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 160 pp.  
PATENT: PCT/EP03/07958  
DOCUMENT TYPE: PCT Int. Appl., 160 pp.  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE  
WO 2003-07958 A1 2003-01-30 WO 2002-EP7416 2002-07-04

W:

AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, SD, SR, SG, SI, SL, TU, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZN, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IR, IT, LU, MC, NL, NE, SN, TD, TG

R:

AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FR, RO, MK, CY, AL, TR, BG, CZ, EE, SK

EP:

10134721 A1 2003-02-06 DE 2001-10134721 2001-07-17

DE:

1011948 A1 2004-02-26 EP 2002-762319 2002-07-04

JP:

2004-516858 T2 2004-12-09 JP 2003-515365 2002-07-04

US:

2004-225849 A1 2004-11-25 US 2004-483464 2004-06-14

PRIORITY APPLN. INFO.:

DE 2001-10134721 A 2001-07-17

OTHER SOURCE(S): MARPAT 138:131142 WO 2002-EP7416 W 20020704

AB The invention discloses tetrahydroquinoline derivs., a method for producing them, and the use thereof for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of painful conditions. The compds. have an affinity for the bradykinin-1 receptor.

IT 491847-64-4P 491848-17-0P 491849-19-1P

491848-19-2P 491848-20-5P 491848-21-6P

491848-42-1P 491848-43-2P 491848-44-3P

491848-45-4P 491848-46-5P

RL: PAC (Pharmacological activity); SPR (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


491848-17-0 CAPLUS  
RN 491848-17-0 CAPLUS  
CN piperazine, 1-(2-methylphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl]-(9CI) (CA INDEX NAME)

use)

491848-17-0 CAPLUS


piperazine, 1-(2-methylphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491848-17-0 CAPLUS  
CN piperazine, 1-(2-methylphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 491848-18-1 CAPLUS  
CN piperazine, 1-(2,4-difluorophenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


NAME:



RN 491848-19-2 CAPLUS  
 CN Piperazine, 1-[(4-fluorophenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Me



RN 491848-20-5 CAPLUS  
 Piperazine, 1-[(2-methoxyphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Me



RN 491848-21-6 CAPLUS  
 Piperazine, 1-[(2-methoxyphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl] - (9CI) (CA INDEX NAME)


NAME:



RN 491848-22-7 CAPLUS  
 CN Piperazine, 2-methyl-1-(3-methylphenyl)sulfonyl-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Me



RN 491848-25-0 CAPLUS  
 Piperazine, 2-methyl-1-phenyl-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Me




RN 491848-41-0 CAPLUS  
 Piperazine, 1-(2,6-dimethylphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxaliny]acetyl] - (9CI) (CA INDEX NAME)


NAME) **Absolute stereochemistry.**




RN 491848-42-1 CAPLUS  
CN Piperazine, 1-[(3-chlorophenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)  
**Absolute stereochemistry.**



RN 491848-43-2 CAPLUS  
CN Piperazine, 1-[(3-methoxyphenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)  
**Absolute stereochemistry.**




RN 491848-45-4 CAPLUS  
CN Piperazine, 1-[(4-chlorophenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)  
**Absolute stereochemistry.**



RN 491848-44-3 CAPLUS  
CN Piperazine, 1-[(3,5-dichlorophenyl)-4-[(2S)-1,2,3,4-tetrahydro-3-oxo-1-[(2,4,6-trimethylphenyl)sulfonyl]-2-quinoxalinyl]acetyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1994605186 CAPLUS  
DOCUMENT NUMBER: 121:205:36  
TITLE: Preparation of quinoxalines as neuroprotectants for cerebral ischemia

INVENTOR(S): Fujimura, Shigeaki; Takai, Haruki; Ikeda, Junichi; Kubo, Kazuhiko  
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 27 Pp.  
CODEN: JGXAF

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO. \_\_\_\_\_ KIND \_\_\_\_\_ DATE \_\_\_\_\_ APPLICATION NO. \_\_\_\_\_ DATE \_\_\_\_\_

**\*CLOSEST PRIOR ART**

JP 05331151 PRIORITY APPN. INFO.: A2 19931214 JP 1992-136752 19920528  
 OTHER SOURCE(S): GI MARPAT 121:205386

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Quinoxaline derivs., e. g. I [A = (substituted) aryl, aralkyl, etc.; R3 = H, (substituted) alkyl, aralkyl; n = 1 - 5; DE = N(C) or RNC; R4 = H, (substituted) arylsulfonyl, etc.], are prepared A mixture of quinoxaline II and 1-(2-methoxyphenyl)piperazine in tBu containing tetra-Bu ammonium bromide and Et3N was refluxed for 9 h to give quinoxalines III and IV (R = H).  
 IV (R = Me) showed min. ED of 3 mg/kg against brain ischemia in mice.

IT

157861-51-3P 157861-54-4P 157861-53-5P  
 157861-54-6P 157861-55-7P 157861-56-8P  
 157861-57-9P 157861-58-0P 157861-61-5P  
 157861-62-6P 157861-63-7P 157861-66-0P  
 157861-65-9P 157861-66-0P 157861-67-1P  
 157861-68-2P 157861-69-3P 157861-70-6P  
 157861-71-7P 157861-72-8P 157861-77-9P  
 157861-74-0P 157861-75-1P 157861-76-2P  
 157861-77-3P 157861-78-4P 157861-79-5P  
 157861-80-8P 157861-81-9P 157861-82-0P  
 157861-83-1P 157861-84-2P 157861-85-3P  
 157861-86-4P 157861-87-5P 157861-89-6P  
 157861-89-7P 157861-90-0P 157861-91-1P  
 157861-92-2P 157861-93-3P 157861-94-4P  
 157861-95-5P 157861-96-6P 157861-97-7P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as neuroprotective agent)

RN CAPLUS 157861-51-3  
 CN 2(1H)-Quinoxaline, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-methyl-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN CAPLUS 157861-52-4  
 CN 2(1H)-Quinoxaline, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl





RN CAPLUS 157861-55-7  
 CN 2(1H)-Quinoxaline, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

● HCl




RN CAPLUS 157861-54-6  
 CN 2(1H)-Quinoxaline, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-methyl-4-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)






**RN** 157861-56-8 **CAPLIUS**  
**CN** 2(1H)-Quinoxaline, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(phenylsulfonyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

**RN** 157861-57-9 **CAPLIUS**  
**CN** 2(1H)-Quinoxaline, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

**RN** 157861-58-0 **CAPLIUS**  
**CN** 2(1H)-Quinoxaline, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




● 2 HCl

**RN** 157861-61-5 **CAPLIUS**  
**CN** 2(1H)-Quinoxaline, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




● 2 HCl

**RN** 157861-62-6 **CAPLIUS**  
**CN** 2(1H)-Quinoxaline, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-(methylsulfonyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


**RN** 157861-63-7 **CAPLIUS**  
**CN** 2(1H)-Quinoxaline, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




● 2 HCl




RN 157861-64-8 CAPLUS  
2(1H)-Quinoxalinone, 3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 157861-67-1 CAPLUS  
2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 157861-65-9 CAPLUS  
2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 157861-66-0 CAPLUS  
2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 157861-69-3 CAPLUS  
2(1H)-Quinoxalinone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-1-methyl-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)






RN 157861-70-6 CAPLUS  
 CN 2-(1H)-Quinoxalimone, 3-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-1-(2-methylpropyl)-4-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 157861-71-7 CAPLUS  
 CN 1-(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)





RN 157861-72-8 CAPLUS  
 CN 1-(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 157861-73-9 CAPLUS  
 CN 1-(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-3-oxo-4-propyl-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 157861-74-0 CAPLUS  
 CN 1-(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-3-oxo-4-propyl-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 157861-75-1 CAPLUS  
 CN 1-(2H)-Quinoxalinecarboxylic acid, 4-butyl-3,4-dihydro-2-[2-[(4-(2-methoxyphenyl)-1-piperazinyl)ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)





● HCl




RN 157861-76-2 CAPTUS  
 1-(2H)-Quinoxalin-1-carboxylic acid, 4-butyl-3,4-dihydro-2-[1-[4-(2-  
 methoxy)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester,  
 dihydrochloride (9CI) (CA INDEX NAME)



RN 157861-77-3 CAPUS  
 CN 1-(2-(2-methoxyphenoxy)-1-piperazinyl)-1-ethyl]-3-oxo-, 2-propenyl ester (9CI)  
 (CA INDEX NAME)




RN 157861-79-5 CAPIUS  
 CN (2'-Quinolinalcarboxylic acid, 4-(cyclohexylmethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) ((CA INDEX NAME))




RN 157861-80-8 CAPIUS  
 CN (2-Methoxyphenyl)-1-piperazinylmethylethyl-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

RN 157861-83-1 CAPLUS  
 1-(2H)-Quinoxalinecarboxylic acid, 4-(2-ethoxyethyl)-3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)




● HCl

RN 157861-81-9 CAPLUS  
 1,2H)-Quinoxalinepropanoic acid, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2-oxo-4-[(2-propenyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 157861-84-2 CAPLUS  
 1-(2H)-Quinoxalinecarboxylic acid, 4-(2-ethoxyethyl)-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 157861-82-0 CAPLUS  
 1-(2H)-Quinoxalinepropanoic acid, 3,4-dihydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-2-oxo-4-[(2-propenyl)carbonyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 157861-85-3 CAPLUS  
 1-(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-4-(phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



● 2 HCl

RN 157861-86-4 CAPLUS  
 1-(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-3-oxo-4-(phenylmethyl)-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN

157861-87-5 CAPLUS 1-(2H-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)


RN

157861-90-0 CAPLUS 1-(2H-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

CN  
1 (2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)

RN

1 (2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN

157861-88-6 CAPLUS 1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

CN

1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN

157861-89-7 CAPLUS 1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)

CN

1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)



● HCl

RN

157861-91-1 CAPLUS 1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-2-oxo-4-[2-propenyl]-, ethyl ester (9CI) (CA INDEX NAME)

CN

1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-2-oxo-4-[2-propenyl]-, ethyl ester (9CI) (CA INDEX NAME)



● HCl

RN

157861-92-2 CAPLUS 1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-2-oxo-4-[2-propenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


CN

1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-2-oxo-4-[2-propenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


RN  
157861-89-7 CAPLUS 1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)

CN


1-(2H)-Quinoxalin-3-yl)-3,4-dihydro-3-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 157861-93-3 CAPLUS  
CN 1-(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(4-fluorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (CA INDEX NAME)




RN 157861-96-6 CAPLUS  
CN 1-(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (CA INDEX NAME)



RN 157861-97-7 CAPLUS  
CN 1-(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-4-methyl-3-oxo-, 2-propenyl ester (CA INDEX NAME)



RN 157861-98-8 CAPLUS  
CN 1-(2H)-Quinoxalinecarboxylic acid, 2-[2-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3,4-dihydro-3-oxo-, 2-propenyl ester, monohydrochloride (CA INDEX NAME)



● HCl

> LOGOFF  
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD: Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:33:08 ON 28 JAN 2005

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.93	197.90
	SINCE FILE ENTRY	TOTAL SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE		
STN INTERNATIONAL LOGOFF AT 11:33:08 ON 28 JAN 2005		